Humanized IgG1 monoclonal antibody targeting OX40 (CD134); inhibits the OX40–OX40L T‑cell costimulatory pathway and depletes OX40+ activated T cells via Fc‑enhanced ADCC, reducing pathogenic effector/memory T‑cell activity and type 2 inflammatory cytokine signaling.
Humanized IgG1 monoclonal antibody against OX40 (CD134) that blocks OX40–OX40L costimulatory signaling and depletes OX40+ activated T cells via Fc-enhanced ADCC, reducing pathogenic effector/memory T-cell activity and type 2 inflammatory cytokine signaling.
YES
DIRECT
The IgG1 antibody binds OX40 on activated T cells and its Fc engages Fcγ receptors on effector cells (e.g., NK cells), triggering Fc‑enhanced ADCC that lyses/depletes OX40+ cells.
Humanized anti-CD19 monoclonal antibody (Monjuvi) optionally used post-infusion to ablate transferred CAR Tregs as a safety measure.
Tafasitamab-cxix is a humanized anti-CD19 monoclonal antibody with an Fc-engineered region that enhances Fcγ receptor binding to promote antibody-dependent cellular cytotoxicity and phagocytosis, leading to depletion of CD19-expressing B cells (and any CD19-tagged engineered cells) for antineoplastic and immunomodulatory effects.
YES
DIRECT
Binds CD19 on target cells and engages Fcγ receptor–bearing effector cells to mediate antibody-dependent cellular cytotoxicity and phagocytosis, depleting CD19+ cells.
HER2-targeted IgG1 monoclonal antibody that blocks ERBB2 signaling and mediates ADCC.
Humanized IgG1 monoclonal antibody targeting HER2/ERBB2; binds the receptor to inhibit HER2 signaling and receptor dimerization, promotes receptor downregulation, and elicits antibody-dependent cell-mediated cytotoxicity (ADCC) against HER2-overexpressing tumor cells.
YES
DIRECT
Trastuzumab binds HER2 on tumor cells and engages FcγR-bearing effector cells (e.g., NK cells, macrophages) to mediate ADCC; it may also trigger complement-dependent cytotoxicity and can promote apoptosis via HER2 signaling blockade.
HER2-targeted antibody–drug conjugate (T-DM1) that delivers the maytansinoid microtubule inhibitor DM1.
HER2-targeted monoclonal antibody (trastuzumab) linked via a nonreducible thioether (MCC) to the maytansinoid DM1; after binding HER2 and internalization, DM1 is released intracellularly to bind tubulin and disrupt microtubule dynamics, inhibiting cell division and inducing cancer cell death. Trastuzumab also inhibits HER2 signaling and can mediate Fc-dependent immune effector functions.
YES
DIRECT
ADC binds HER2, is internalized, and releases the DM1 payload that binds tubulin, disrupting microtubules and causing mitotic arrest and apoptosis; Fc effector functions (e.g., ADCC) may add killing.
HER2-targeted antibody–drug conjugate (T-DM1) that delivers the maytansinoid microtubule inhibitor DM1.
HER2-targeted monoclonal antibody (trastuzumab) linked via a nonreducible thioether (MCC) to the maytansinoid DM1; after binding HER2 and internalization, DM1 is released intracellularly to bind tubulin and disrupt microtubule dynamics, inhibiting cell division and inducing cancer cell death. Trastuzumab also inhibits HER2 signaling and can mediate Fc-dependent immune effector functions.
NO
INDIRECT
T-DM1 binds HER2, is internalized, then releases DM1 that binds beta-tubulin to disrupt microtubules and induce apoptosis. Beta-tubulin expression alone does not lead to killing without HER2-mediated uptake.